CNBX Pharmaceuticals (OTCMKTS:CNBX – Get Rating) is one of 355 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare CNBX Pharmaceuticals to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Analyst Recommendations
This is a summary of recent recommendations and price targets for CNBX Pharmaceuticals and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CNBX Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| CNBX Pharmaceuticals Competitors | 319 | 1581 | 4324 | 48 | 2.65 |
As a group, “Biotechnology” companies have a potential upside of 78.31%. Given CNBX Pharmaceuticals’ competitors higher possible upside, analysts plainly believe CNBX Pharmaceuticals has less favorable growth aspects than its competitors.
Valuation & Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CNBX Pharmaceuticals | N/A | N/A | -3.88 |
| CNBX Pharmaceuticals Competitors | $120.80 million | -$13.93 million | 54.31 |
CNBX Pharmaceuticals’ competitors have higher revenue, but lower earnings than CNBX Pharmaceuticals. CNBX Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares CNBX Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CNBX Pharmaceuticals | N/A | N/A | N/A |
| CNBX Pharmaceuticals Competitors | -2,654.25% | -395.73% | -20.31% |
Institutional & Insider Ownership
98.2% of CNBX Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of shares of all “Biotechnology” companies are owned by institutional investors. 73.5% of CNBX Pharmaceuticals shares are owned by company insiders. Comparatively, 27.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
CNBX Pharmaceuticals beats its competitors on 5 of the 8 factors compared.
CNBX Pharmaceuticals Company Profile
CNBX Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. The company was founded by Eyal Barad on September 15, 2004 and is headquartered in Bethesda, MD.
Receive News & Ratings for CNBX Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNBX Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
